COVID-19 Treatments

COVID-19 Treatments

Rolling Collaborative Reviews (RCR)

Please access the RCR project plan and all separate RCR documents, updated on a monthly or bi-monthly basis, in the following table.

Note: Due to the EUnetHTA Assembly & Forum that is taking place on the 14-15 April 2021, the publication of the April round of RCRs will be shifted to the 20 April.

Project IDTitleVersion of RCR publishedAuthorStart of Procedure ContinuationPublication of Project Plan
RCR01Convalescent plasma therapy / CPT 8.0 – 15/03/21HTWAugust 2020Yes, monthly01.07.2020 – RCRs Project Plan
RCR02Lopinavir + Ritonavir4.0 – 23/11/20National Institute of Pharmacy and Nutrition – NIPNAugust 2020No, stopped with November 2020 
RCR03Tocilizumab8.0 – 15/03/21National Institute of Pharmacy and Nutrition – NIPNAugust 2020Yes, monthly 
RCR04Camostat7.0 – 15/03/21Belgian Health Care Knowledge Centre – KCEAugust 2020Yes, monthly 
RCR05Nafamostat6.0 – 15/02/21Belgian Health Care Knowledge Centre – KCEAugust 2020Yes, monthly 
RCR06Solnatide5.0 – 15/02/21Austrian Institute for Health Technology Assessment – AIHTAAugust 2020Yes, bi-monthly 
RCR07Anakinra8.0 – 15/03/21Austrian Institute for Health Technology Assessment – AIHTAAugust 2020Yes, monthly 
RCR08Dexamethasone2.0 – 15/09/20Austrian Institute for Health Technology Assessment – AIHTAAugust 2020No, stopped with October 2020 
RCR09APN015.0 – 15/02/21Agencia Española De Medicamentos Y Productos Sanitarios – AEMPS, Andalusian HTA Agency,
Ministry of Health – AETSA
August 2020Yes, bi-monthly 
RCR10Darunavir8.0 – 15/03/21Swiss Network for HTA – SNHTAAugust 2020Yes, monthly 
RCR11Favipiravir8.0 – 15/03/21Swiss Network for HTA – SNHTAAugust 2020Yes, monthly 
RCR12Sarilumab8.0 – 15/03/21Norwegian Institute of Public Health – NIPHAugust 2020Yes, monthly 
RCR13Interferon and Novaferon7.0 – 15/03/21Norwegian Institute of Public Health – NIPHSeptember 2020Yes, monthly 
RCR14Gimsilumab2.0 – 15/09/20State Medicines Control Agency of Lithuania – SMCAAugust 2020Yes, bi-monthly 
RCR15Canakinumab4.0 – 15/02/21State Medicines Control Agency of Lithuania – SMCAAugust 2020Yes, bi-monthly 
RCR16REGN-COV2 (Casirivimab + Imdevimab)3.0 – 15/02/21Austrian Institute for Health Technology Assessment – AIHTADecember 2020No, stopped with February 2021 
RCR17Bamlanivimab (LY-CoV555)3.0 – 15/02/21Austrian Institute for Health Technology Assessment – AIHTADecember 2020No, stopped with February 2021 
RCR18Baricitinib (LY3009104)4.0 – 15/03/21Austrian Institute for Health Technology Assessment – AIHTADecember 2020Yes, monthly 
RCR19Molnupiravir (MK 4482/ EIDD-28014.0 – 15/03/21Austrian Institute for Health Technology Assessment – AIHTADecember 2020Yes, monthly 
RCR20High-dose vitamin D2.0 – 15/03/21Gesundheit Österreich GmbH – GÖGFebruary 2021Yes, monthly 
RCR21Mavrilimumab2.0 – 15/03/21Servicio de Evaluación del Servicio Canario de la Salud – SESCSJanuary 2021Yes, monthly 
RCR22Ivermectin2.0 – 15/03/21Agency for Health Technology Assessment and Tariff System – AOTMiTFebruary 2021Yes, monthly 
RCR23Aspirin2.0 – 15/03/21Swiss Network for HTA – SNHTAFebruary 2021Yes, monthly 

*For monthly updated RCRs, the RCR authors search for new available evidence on a monthly basis. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published, and the search is repeated in the subsequent month.

For bi-monthly updated RCRs, the RCR authors search for new available evidence every other month. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published and the search is repeated after 2 months.

Please access a description of methods used in the RCR process here.

Stopping & Starting Rules for RCR

Stopping Rules

  • The decision to stop an RCR will be taken collectively in the RCR team.
  • A discussion about stopping an RCR will be started when either stopping rule 1 OR stopping rule 2 is met.
  • The stopping rules act as orientation/ reference for the discussion in the team; an RCR may not be stopped although one of the rules apply if the team comes to a different conclusion due to any sound reason.

Stopping rule 1:

The compound is in EMA’s marketing authorization process or has a positive marketing authorization decision.

Stopping rule 2:

No clinical benefit: ≥ 2 RCTs OR treatment arms in platform trials (e.g., RECOVERY) with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered).

OR ≥1 RCT with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered) AND stopped enrollment of participants to the treatment arm of interest in a platform trial (e.g., RECOVERY) because no evidence of beneficial effects.

  • To be considered for the discussion:
    • Amount and number of included patients of ongoing RCTs and upcoming RCTs

Starting rules

  • The decision to start an RCR will be taken collectively in the RCR team.
  • A discussion about starting an RCR will be started when one of the starting rules is met.
  • The starting rules act as orientation/ reference for the discussion in the team; an RCR may not be started although one of the rules apply if the team comes to a different conclusion due to any sound reason.

Starting rule 1:

Published results from ≥ 1 phase III RCT with positive efficacy and safety results in the indication and population under review (high or moderate quality, non peer-reviewed or peer-reviewed article).

  • Confirmed by DEPLazio or RCT found on covid-nma.com

Starting rule 2:

Upcoming (promising) evidence of ≥ 2 phase III trials.

Starting rule 3:

Compound included as trial drug in a platform trial on COVID-19 treatments.

Starting rule 4:

Combination therapy of ≥ 2 promising pharmaceuticals – the combination will be reviewed as a separate intervention.

Starting rule 5:

Interest from ≥ 2 EUnetHTA Partners (via survey) OR Interest from MAH to seek marketing approval OR Interest from EC, HTA Network or EUnetHTA Stakeholder Groups.

Rapid Collaborative Reviews

Please access the Rapid Collaborative Reviews in the following table.

Project IDTitlePublication of Final ReviewAuthorCo-AuthorDedicated ReviewerPublication of Project Plan
PTRCR20Bamlanivimab for the treatment of COVID-19
Rapid Collaborative Review
TBCAIHTA SNHTASESCS, SUKLNA
PTRCR19 REGN-Cov2 for the treatment of COVID-19
Rapid Collaborative Review
TBCAIHTA SNHTAGÖG, UCSC GemelliNA
PTRCR18Dexamethasone for the treatment of COVID-19
Rapid Collaborative Review
19.11.2020AIHTASNHTARER, MoH UkraineNA
PTRCR15

Remdesivir for the treatment of COVID-19

First update

First update: 16.12.2020AIHTANAINFARMED, NCPE, RER, MoH UkraineNA
Rapid Collaborative Review: PICO and Evidence gapsOriginal report: 29.09.2020INFARMEDNCPEAIHTA, RER, MoH UkraineNA

National HTA Organisation Treatment Links

Links will be published here that relate to relevant partner organisation outputs on Covid-19.

Austrian Institute for Health Technology Assessment (AIHTA) – Horizon scanning for Covid-19 treatments:

http://eprints.aihta.at/1234/

Country Organisation Date of publication HTA reviews/assessments on Covid testing
Ireland NCPE 25/02/21 Rapid Evidence Review – Tocilizumab in the management of COVID-19
UK NICE 24/02/21 COVID-19 rapid evidence summary: Tocilizumab for COVID-19
Ireland NCPE 19/02/21 Intravenous immunoglobulin for the treatment of COVID-19: A Rapid Evidence Review
Ireland NCPE 05/02/21 Rapid Evidence Review – Clinical evidence for the use of antivirals in the treatment of COVID-19
Spain AEMPS 25/01/21 1º Informe de Farmacovigilancia sobre vacunas COVID-19 (Pharmacovigilance Report on Vaccines COVID-19)
UK NICE National Institute for Health and Care Excellence 20/01/21 COVID-19 rapid evidence summary: Sarilumab for COVID-19
UK NICE National Institute for Health and Care Excellence 15/01/21 COVID-19 rapid evidence summary: Sarilumab for COVID-19
Italy AIFA 13/01/21 Vaccini COVID-19 (Covid-19 vaccines)
Portugal INFARMED National Authority of Medicines and Health Products 23/12/20 Vacinas COVID-19 (Covid-19 vaccines)
Spain AEMPS 15/12/20 Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
France HAS 01/12/20 Aspects immunologiques et virologiques de l’infection par le SARS-CoV-2 (Immunological and virological aspects of SARS-CoV-2 infection)
Italy AIFA 25/11/20 Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 (Hydroxychloroquine in the treatment of adult patients with COVID-19)
Italy AIFA 25/11/20 Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 (Hydroxychloroquine in the treatment of adult patients with COVID-19)
Italy AIFA 24/11/20 Eparine a basso peso molecolare nei pazienti adulti con COVID-19 (Low molecular weight heparins in adult patients with COVID-19)
Italy AIFA 24/11/20 Remdesivir nella terapia dei pazienti adulti con COVID-19 (Remdesivir in the therapy of adult patients with COVID-19)
France HAS 10/11/20 Tests diagnostiques pour différencier la COVID-19 des infections respiratoires hivernales en période de co-circulation des virus (Diagnostic tests to differentiate COVID-19 from winter respiratory infections in periods of virus co-circulation)
Ireland NCPE 23/10/20 Clinical evidence for the use of antivirals in the treatment of COVID-19
Spain AEMPS 23/10/20 Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
Spain AEMPS 23/10/20 Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
Ireland NCPE 22/10/20 Rapid Evidence Review – Clinical evidence for the use of antivirals in the treatment of COVID-19
Italy AIFA 06/10/20 Corticosteroidi nella terapia dei pazienti adulti con COVID-19 (Corticosteroids in the therapy of adult patients with COVID-19)
Spain AEMPS 02/10/20 Información sobre investigación clínica sobre la COVID-19 (Information on clinical research on COVID-19)
France HAS 25/09/20 Veille des études cliniques publiées pour certains médicaments du Covid-19 (Monitoring of published clinical studies for certain Covid-19 drugs)
Spain AQuAS 22/09/20 Símptomes de llarga durada o persistents en pacients amb infecció lleu-moderada per SARS-CoV-2 (COVID-19): revisió ràpida de la literatura i discussió del’evidència disponible (Long-term or persistent symptoms in patients with moderate SARS-CoV-2 infection (COVID-19): rapid literature review and discussion of available evidence )
Poland AOTMiT 28/08/20 Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
Ireland NCPE 21/08/20 Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
Finland FIMEA 07/08/20 Fimea julkaisi arviointikoosteen remdesiviiristä COVID-19-taudin hoidossa (Fimea has published a summary of the evaluation of remdesivirir in the treatment of COVID-19)
Poland AOTMIT 06/08/20 Przegląd doniesień naukowych dla kortykosteroidów stosowanych w COVID-19 (Assessment of the scientific reports for corticosteroids used in COVID-19 (version 1.0))
Poland AOTMIT 05/08/20 Przegląd doniesień naukowych dla lopinawiru/rytonawiru stosowanych w COVID-19 (Overview of the scientific reports for lopinavir / ritonavir used in COVID-19 (version 1.0))
UK NICE 05/06/20 COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
Italy AIFA 17/07/20 Darunavir/cobicistat nella terapia dei pazienti adulti con COVID-19 (Darunavir / cobicistat in the treatment of adult patients with COVID-19 )
Italy AIFA 17/07/20 Lopinavir/ritonavir nella terapia dei pazienti adulti con COVID-19 (Lopinavir / ritonavir in the treatment of adult patients with COVID-19 )
Italy AIFA 17/07/20 Farmaci utilizzabili per il trattamento della malattia COVID-19 (Drugs usable for the treatment of the disease COVID-19)
Wales HTW ??/07/20 Cytokine adsorbers for the treatment of cytokine storm in people with severe coronavirus infection
UK NICE National Institute for Health and Care Excellence 29/06/20 COVID-19 rapid evidence summary: vitamin D for COVID-19
UK NICE National Institute for Health and Care Excellence 05/06/20 COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
Ukraine MoH Ukraine 22/05/20 Застосування ліків при COVID-19 (The use of drugs in COVID-19)
UK NICE National Institute for Health and Care Excellence 24/03/20 COVID-19 rapid evidence summary: acute use of nonsteroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19